RxDoctor Payments Data

Nicole Fein, PA

Surgical · New York, NYNPI 1205933645

Payments from drug & device makers

What this record shows

This record is dominated by other: $224,345 of the $225,056 with a category attached, or 99.7%. Smith+Nephew accounts for 99.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $201,279 and has fallen 96.4% since, to $7,314 in 2025. Among surgical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$225,056in general payments, 2019–2025

Across 14 payments — averaging $16,075 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$224K
  • Stryker$299
  • Johnson & Johnson$125
  • Medical Device Business Services, Inc.$125
  • Merit Medical Systems Inc$78
  • Molnlycke Health Care US, LLC$21

What the payments were for

  • Food & beverage$7110%
  • Other$224,345100%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$225,056 in reported general payments places this provider in the 95th percentile of 1,544 surgical providers in New York.

See all surgical providers in New York

Medicare billing

Part B allowed, 2024
$38,622
Medicare patients
102
Services billed
2,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam43$160
Diclofenac Sodium13$154
Oxycodone Hcl19$108
Amoxicillin21$56
Clindamycin Hcl13$48

Paid to pharmacies, not to this prescriber.

Other surgical in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →